Peripheral insulin and amylin levels in Parkinson's disease

What Was Tested

This observational study looks at Amylin (Islet Amyloid Polypeptide) in the context of parkinson's disease.

The researchers aimed to assess peripheral levels of amylin and insulin in PD patients and control subjects (Cs).

Why It Was Studied

Type-2-diabetes (T2D) has surfaced as a potential risk factor for Parkinson's disease (PD) in some epidemiological studies.

Evidence of glucose metabolism alterations in PD from molecular studies remains conflicting.

Who Took Part

According to the abstract, 111 participants were involved.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

The researchers conducted an observational cross-sectional study of 111 participants: 73 PD and 38 Cs, similar in age, sex and body mass index.

How the Study Was Run

All underwent motor (UPDRS-MDS-III), non-motor (NMSS) and cognitive (MDRS) scales as well as determination of four parameters: fasting glycaemia, glycated haemoglobin, fasting plasma insulin (FPI) and fasting plasma amylin (FPA).

What Was Measured

Topics PubMed links to this paper include Age Factors, Cross-Sectional Studies, Insulin, Insulin Resistance, Islet Amyloid Polypeptide and Parkinson Disease.

The authors tagged it with the keywords Amylin, Glucose metabolic alterations and Parkinson's disease.

What This Means in Plain Language

This is an observational study of Amylin (Islet Amyloid Polypeptide) in 111 participants in people with parkinson's disease.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Parkinsonism & related disorders), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, Parkinson's disease research.